Elimusertib (hydrochloride)

[1]Ulrich T. Luecking, et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement.|[2]Antje Margret Wengner, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement|[3]Ulrich Lücking, et al. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem. 2020 Jul 9;63 (13) :7293-7325.

Cancer Res. 2022 Mar 15;82 (6) :1013-1024.|RSC Adv. 2025 Jun 16;15 (26) :20385-20396.|Biochem Pharmacol. 2023 May:211:115494.|bioRxiv. 2025 Sep 30.|Cell Rep Med. 2025 May 6:102129.|EMBO Rep. 2024 Mar;25 (3) :1469-1489.|Exp Mol Med. 2025 Feb;57 (1) :167-183.|J Med Chem. 2024 Feb 22;67 (4) :2349-2368.|Mol Cell Biol. 2025;45 (3) :99-115.|Nat Commun. 2024 Oct 24;15 (1) :9195.|Research Square Preprint. 2023 Jun 9.|Research Square Preprint. 2023 May 17.|Research Square Preprint. 2023 Nov 20.